Free Trial
NASDAQ:AURA

Aura Biosciences Q1 2025 Earnings Report

Aura Biosciences logo
$6.43 -0.01 (-0.16%)
Closing price 04:00 PM Eastern
Extended Trading
$6.43 0.00 (0.00%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aura Biosciences EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.47
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Aura Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aura Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
6:00AM ET

Upcoming Earnings

Aura Biosciences' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Aura Biosciences Earnings Headlines

Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
Research Analysts Offer Predictions for AURA Q3 Earnings
Aura Biosciences Posts Q2 Cash Surge
See More Aura Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aura Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aura Biosciences and other key companies, straight to your email.

About Aura Biosciences

Aura Biosciences (NASDAQ:AURA), a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

View Aura Biosciences Profile

More Earnings Resources from MarketBeat